MannKind  logo
MNKDMannKind
Trade MNKD now
MannKind  primary media

About MannKind

MannKind (NASDAQ:MNKD) is dedicated to discovering, developing, and commercializing innovative therapeutic products for patients with diseases such as diabetes. Central to its portfolio is Afrezza, an inhalable insulin offering a unique administration method compared to traditional insulin delivery mechanisms, aimed at improving the quality of life for those managing their diabetes. Beyond diabetes, MannKind is exploring opportunities to leverage its technosphere technology platform to create inhalable therapeutic products for other conditions. Their objective is to expand the application of their technology to address unmet medical needs across various diseases, pushing the boundaries of what's possible in medical science and improving patient outcomes.

What is MNKD known for?

Snapshot

Public US
Ownership
1991
Year founded
535
Employees
Connecticut, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of MannKind

  • Afrezza, an inhalable insulin for adults with diabetes, offers a rapid-acting mealtime blood sugar control alternative.
  • Technosphere technology, a versatile pulmonary drug delivery platform designed to improve medication efficacy and patient compliance.
  • Tyvaso DPI, developed in collaboration with United Therapeutics for pulmonary arterial hypertension, leverages Technosphere for targeted delivery.
  • Epalrestat inhalation powder, an investigational treatment for diabetic peripheral neuropathy, aiming to reduce symptoms and progression.
  • Collaboration with Vertice Pharma to create inhalable treatments for orphan lung diseases, expanding therapeutic options for rare conditions.
  • MannKind is exploring inhaled therapeutic options for oncology, aiming to develop innovative treatments for cancer patients.

MannKind executive team

  • Dr. Michael E. Castagna Pharm.D.CEO & Director
  • Mr. Christopher B. Prentiss M.B.A.Chief Financial Officer
  • Dr. David B. Thomson J.D., Ph.D.Executive VP, General Counsel & Secretary
  • Mr. Sanjay Singh M.B.A.Executive Vice President of Technical Operations
  • Dr. Stuart A. Tross Ph.D.Chief People & Workplace Officer
  • Mr. Dominic Marasco R.Ph.President of Endocrine Business Unit
  • Dr. Ajay Ahuja M.B.A., M.D.Chief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.